Impact of Early Initiation of Eslicarbazepine Acetate on Economic Outcomes Among Patients with Focal Seizure: Results from Retrospective Database Analyses
Abstract Introduction This study assessed the association between early initiation of eslicarbazepine acetate (ESL) as first-line therapy (1L cohort) or as first adjunctive regimen to either levetiracetam (LEV) or lamotrigine (LTG) (add-on cohort), and healthcare resource utilization (HCRU) and char...
Main Authors: | Darshan Mehta, Matthew Davis, Andrew J. Epstein, Brian Wensel, Todd Grinnell, G. Rhys Williams |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2020-09-01
|
Series: | Neurology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40120-020-00211-6 |
Similar Items
-
Comparative Economic Outcomes in Patients with Focal Seizure Initiating First-Line Eslicarbazepine Acetate Monotherapy versus Generic Antiseizure Drugs
by: Mehta D, et al.
Published: (2021-04-01) -
Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures
by: Hamada Altalib, et al.
Published: (2022-12-01) -
Healthcare Resource Utilization Pre- and Post-Initiation of Eslicarbazepine Acetate Among Pediatric Patients with Focal Seizure: Evidence from Routine Clinical Practice
by: Mehta D, et al.
Published: (2020-07-01) -
Eslicarbazepine acetate: An efficacy and safety as an antiepileptic drug in clinical trials and open studies
by: Martyna Stefaniak, et al.
Published: (2022-02-01) -
Eslicarbazepine acetate: A therapeutic agent of paramount importance in acute anticonvulsant therapy
by: Farah Iram, et al.
Published: (2017-01-01)